Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | BTK | Q06187 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | CTSL | P07711 | 2/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | PREP | P48147 | 1/20 | 0.31 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.31 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.31 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2429386 | 0.87 | SMN1; SMN2 (0.39) | SMN1; SMN2HPGDKMT2AHRH3LMNA | |
| SCHEMBL2434806 | 0.86 | ALDH1A1 (0.46) | SMN1; SMN2KMT2AHRH3CTSLMEN1 | |
| SCHEMBL9935314 | 0.80 | HSD17B10 (0.36) | HSD17B10SMN1; SMN2HPGDBTKKMT2A | |
| SCHEMBL2434333 | 0.76 | SMN1; SMN2 (0.37) | HSD17B10SMN1; SMN2HPGDBTKKMT2A | |
| SCHEMBL5681663 | 0.73 | GAA (0.33) | HSD17B10HPGDKMT2ALMNAMEN1 | |
| SCHEMBL2429488 | 0.72 | TSHR (0.33) | HPGDLMNATSHR | |
| SCHEMBL3825201 | 0.71 | HSD17B10 (0.45) | HSD17B10SMN1; SMN2HPGDBTKKMT2A | |
| SCHEMBL71018 | 0.70 | ALDH1A1 (0.42) | HSD17B10SMN1; SMN2KMT2AMEN1ALDH1A1 | |
| SCHEMBL71003 | 0.70 | HSD17B10 (0.36) | HSD17B10SMN1; SMN2HPGDBTKKMT2A | |
| SCHEMBL6991986 | 0.69 | HSD17B10 (0.41) | HSD17B10SMN1; SMN2HPGDBTKKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1346982-B1 | VLA-4 INHIBITORS | DAIICHI SEIYAKU CO (JP) | 2011-09-14 | — | — | EP | disclosed |
| US-7157487-B2 | Vla-4 inhibitors | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2007-01-02 | — | — | US | disclosed |
| US-20040110945-A1 | Vla-4 inhibitors | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2004-06-10 | — | — | US | disclosed |
| EP-1346982-A1 | VLA-4 INHIBITORS | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2003-09-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040110945-A1 | Vla-4 inhibitors | VCAM1, ITGA1, ITGB4 | HSD17B10 1607/4885SMN1; SMN2 3702/4885HPGD 4476/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.